Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

Key facts

Study ID

NCT05048056

Run by

Akesobio Australia Pty Ltd

People needed

79

Starts

2021-09-30

Expected to finish

2023-05-17

Last updated by the study team

2025-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• AkesoBio Investigative Site 2003 — Little Rock, Arkansas, United States
• AkesoBio Investigative Site 2010 — Canoga Park, California, United States
• AkesoBio Investigative Site 2021 — San Diego, California, United States
• AkesoBio Investigative Site 2023 — San Diego, California, United States
• AkesoBio Investigative Site 2017 — San Francisco, California, United States
• AkesoBio Investigative Site 2020 — Sherman Oaks, California, United States
• AkesoBio Investigative Site 2009 — Hialeah, Florida, United States
• AkesoBio Investigative Site 2001 — Hollywood, Florida, United States
• AkesoBio Investigative Site 2011 — Miami, Florida, United States
• AkesoBio Investigative Site 2002 — Weston, Florida, United States
• AkesoBio Investigative Site 2022 — Ridgeland, Mississippi, United States
• AkesoBio Investigative Site 2015 — Las Vegas, Nevada, United States
• AkesoBio Investigative Site 2013 — Spartanburg, South Carolina, United States
• AkesoBio Investigative Site 2005 — Rapid City, South Dakota, United States
• AkesoBio Investigative Site 2004 — Houston, Texas, United States
• AkesoBio Investigative Site 2018 — Houston, Texas, United States
• AkesoBio Investigative Site 3003 — Sydney, New South Wales, Australia
• AkesoBio Investigative Site 3002 — Woolloongabba, Queensland, Australia
• AkesoBio Investigative Site 3001 — Camberwell, Victoria, Australia
• AkesoBio Investigative Site 4003 — Auckland, New Zealand
• AkesoBio Investigative Site 4001 — Auckland, New Zealand
• AkesoBio Investigative Site 4005 — Christchurch, New Zealand
• AkesoBio Investigative Site 4004 — Hamilton, New Zealand
• AkesoBio Investigative Site 4004 — Wellington, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.